justbacked

Artificial Intelligence (AI), Biotechnology, Life Science, Medical, Pharmaceutical, Therapeutics

BigHat Biosciences

BigHat Biosciences raised $75M in a Series C announced on Sep 24, 2026, led by Andreessen Horowitz, S32, Catalio Capital Management, Eli Lilly, 8VC. Since then it has posted 2 roles (2 still open), the first 25 days after it. With 13 open roles it is hiring more than 27% of the 83 Series C startups on JustBacked (median: 22). In total it has raised $174M over 4 rounds from 11 investors.

Roles posted per month since the round
  • October 20261
  • November 20261

From BigHat Biosciences's own hiring system, by posting date. Tracked since Oct 4, 2026; roles that closed before then aren't counted.

BigHat Biosciences develops antibody and protein therapeutics using machine learning, synthetic biology, and automated experimentation.

Why join BigHat Biosciences?

The bet: machine learning and automated experiments can design antibody drugs faster than traditional discovery, and BigHat Biosciences, a San Mateo biotech, is staking the company on it. If it pays off, drug discovery timelines could shrink, and Eli Lilly, already an investor, has released a model built on data from its Milliner platform. A $75M Series C lifts total funding to $174M, and 15 open roles signal a team that is scaling.

JustBacked's take, based on BigHat Biosciences's own site and its funding and hiring data.

Series C · $75M · 58d agobighatbio.com

Hiring velocity

Open roles
13
Added, 30 days
+1
Added, 7 days
+1
Closed, 30 days
4
Raised
58 days ago
Led by
Andreessen Horowitz, S32, Catalio Capital Management, Eli Lilly, 8VC
Team size
51-100
HQ
San Mateo, California, United States
Newest role
2d ago
Tracked since
Oct 4, 2026

Where they're hiring

Data & ML3
Operations3
Science2
Engineering2
People1
Finance1

Open roles at BigHat Biosciences

Source: bighatbio.com, checked daily.